Compelling evidence for a prostate cancer gene at 22q12.3 by the international consortium for prostate cancer genetics

Nicola J. Camp, Lisa A. Cannon-Albright, James M. Farnham, Agnes B. Baffoe-Bonnie, Asha George, Isaac Powell, Joan E. Bailey-Wilson, John D. Carpten, Graham G. Giles, John L. Hopper, Gianluca Severi, Dallas R. English, William D. Foulkes, Lovise Maehle, Pal Moller, Ros Eeles, Douglas Easton, Michael D. Badzioch, Alice S. Whittemore, Ingrid Oakley-GirvanChih Lin Hsieh, Latchezar Dimitrov, Jianfeng Xu, Janet L. Stanford, Bo Johanneson, Kerry Deutsch, Laura McIntosh, Elaine A. Ostrander, Kathleen E. Wiley, Sarah D. Isaacs, Patrick C. Walsh, Stephen N. Thibodeau, Shannon K. McDonnell, Scott Hebbring, Daniel J. Schaid, Ethan M. Lange, Kathleen A. Cooney, Teuvo L.J. Tammela, Johanna Schleutker, Thomas Paiss, Christiane Maier, Henrik Grönberg, Fredrik Wiklund, Monica Emanuelsson, William B. Isaacs

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Previously, an analysis of 14 extended, high-risk Utah pedigrees localized in the chromosome 22q linkage region to 3.2 Mb at 22q12.3-13.1 (flanked on each side by three recombinants) contained 31 annotated genes. In this large, multi-centered, collaborative study, we performed statistical recombinant mapping in 54 pedigrees selected to be informative for recombinant mapping from nine member groups of the International Consortium for Prostate Cancer Genetics (ICPCG). These 54 pedigrees included the 14 extended pedigrees from Utah and 40 pedigrees from eight other ICPCG member groups. The additional 40 pedigrees were selected from a total pool of 1213 such that each pedigree was required to contain both at least four prostate cancer (PRCA) cases and exhibit evidence for linkage to the chromosome 22q region. The recombinant events in these 40 independent pedigrees confirmed the previously proposed region. Further, when all 54 pedigrees were considered, the three-recombinant consensus region was narrowed down by more than a megabase to 2.2 Mb at chromosome 22q12.3 flanked by D22S281 and D22S683. This narrower region eliminated 20 annotated genes from that previously proposed, leaving only 11 genes. This region at 22q12.3 is the most consistently identified and smallest linkage region for PRCA. This collaborative study by the ICPCG illustrates the value of consortium efforts and the continued utility of linkage analysis using informative pedigrees to localize genes for complex diseases.

Original languageEnglish (US)
Pages (from-to)1271-1278
Number of pages8
JournalHuman molecular genetics
Volume16
Issue number11
DOIs
StatePublished - Jun 2007

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Fingerprint Dive into the research topics of 'Compelling evidence for a prostate cancer gene at 22q12.3 by the international consortium for prostate cancer genetics'. Together they form a unique fingerprint.

  • Cite this

    Camp, N. J., Cannon-Albright, L. A., Farnham, J. M., Baffoe-Bonnie, A. B., George, A., Powell, I., Bailey-Wilson, J. E., Carpten, J. D., Giles, G. G., Hopper, J. L., Severi, G., English, D. R., Foulkes, W. D., Maehle, L., Moller, P., Eeles, R., Easton, D., Badzioch, M. D., Whittemore, A. S., ... Isaacs, W. B. (2007). Compelling evidence for a prostate cancer gene at 22q12.3 by the international consortium for prostate cancer genetics. Human molecular genetics, 16(11), 1271-1278. https://doi.org/10.1093/hmg/ddm075